Erratum to: Pretransplant Sensitization Against Angiotensin II Type 1 Receptor Is a Risk Factor for Acute Rejection and Graft Loss: Anti-AT1R-Abs Shorten Graft Survival (American Journal of Transplantation, (2013), 13, 10, (2567-2576), 10.1111/ajt.12397);Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss

American Journal of Transplantation

Volumn 13, Issue 10, 2013, Pages 2567-2576

  Giral, M ^a,b,c   Foucher, Y ^a,b,c,d   Dufay, A ^a   Van Huyen, J P D ^a   Renaudin, K ^b   Moreau, A ^e   Philippe, A ^f   Hegner, B ^f   Dechend, R ^f   Heidecke, H ^g   Brouard, S ^a   Cesbron, A ^h   Castagnet, S ^h   Devys, A ^h   Soulillou, J P ^a   Dragun, D ^f  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d Universite de Nantes   (France)

^e Service d'Anatomo pathologie   (France)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g CellTrend   (Germany)

^h ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

Acute allograft rejection; allosensitization; angiotensin II receptors; antibody mediated rejection; pretransplant; survival

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTIBODY; ANTIBODY; ANTIHYPERTENSIVE AGENT; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HLA ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY MEDIATED REJECTION; ANTIBODY RESPONSE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHEMOSENSITIZATION; COMPLEMENT DEPENDENT CYTOTOXICITY; DELAYED GRAFT FUNCTION; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK PATIENT; HLA SYSTEM; HLA TYPING; HUMAN; HYPERTENSION; IMMUNIZATION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT HYPERTENSION; PREECLAMPSIA; PREOPERATIVE EVALUATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RISK FACTOR; STEROID THERAPY; SYSTOLIC BLOOD PRESSURE;

ACUTE ALLOGRAFT REJECTION; ALLOSENSITIZATION; ANGIOTENSIN II RECEPTORS; ANTIBODY MEDIATED REJECTION; PRETRANSPLANT; SURVIVAL;

ACUTE DISEASE; ADULT; AUTOANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RECEPTOR, ANGIOTENSIN, TYPE 1; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84884902962     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.16099     Document Type: Erratum

References (25)

1. Colvin RB., Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046-1056.
2. Opelz G., Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365: 1570-1576.
3. Dragun D., Humoral responses directed against non-human leukocyte antigens in solid-organ transplantation. Transplantation 2008; 86: 1019-1025.
4. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558-569.
5. Ingelfinger JR., Agonistic autoantibodies and rejection of renal allografts. N Engl J Med 2005; 352: 617-619.
6. Giral-Classe M, Hourmant M, Cantarovich D, et al. Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys. Kidney Int 1998; 54: 972-978.
7. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
8. Horthorn T, Zeileis A., Generalized maximally selected statistics. Biometrics 2008; 64: 1263-1269.
9. Therneau T, Grambsch P., Modeling survival data: Extending the Cox model (statistics for biology and health). New York: Springer, 2001.
10. Thway TM, Shlykov SG, Day MC, et al. Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation 2004; 110: 1612-1619.
11. Zou Y, Stastny P, Susal C, Dohler B, Opelz G., Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357: 1293-1300.
12. Lemy A, Andrien M, Wissing KM, et al. Major histocompatibility complex class 1 chain-related antigen a antibodies: Sensitizing events and impact on renal graft outcomes. Transplantation 2010; 90: 168-174.
13. Leffell MS, Zachary AA., Anti-allograft antibodies: Some are harmful, some can be overcome, and some may be beneficial. Discov Med 2010; 9: 478-484.
14. Nankivell BJ, Alexander SI., Rejection of the kidney allograft. N Engl J Med 2010; 363: 1451-1462.
15. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B., Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383.
16. Martin L, Guignier F, Mousson C, Rageot D, Justrabo E, Rifle G., Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation 2003; 76: 395-400.
17. Dragun D, Philippe A, Catar R, Hegner B., Autoimmune mediated G-protein receptor activation in cardiovascular and renal pathologies. Thromb Haemost 2009; 101: 643-648.
18. Le Bas-Bernardet S, Hourmant M, Coupel S, Bignon JD, Soulillou JP, Charreau B., Non-HLA-type endothelial cell reactive alloantibodies in pre-transplant sera of kidney recipients trigger apoptosis. Am J Transplant 2003; 3: 167-177.
19. Stegbauer J, Lee DH, Seubert S, et al. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci USA 2009; 106: 14942-14947.
20. Verlohren S, Muller DN, Luft FC, Dechend R., Immunology in hypertension, preeclampsia, and target-organ damage. Hypertension 2009; 54: 439-443.
21. Riemekasten G, Philippe A, Nather M, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011; 70: 530-536.
22. Reinsmoen NL, Lai CH, Heidecke H, et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010; 90: 1473-1477.
23. Hiemann NE, Meyer R, Wellnhöfer E, et al. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 2012; 94: 919-924.
24. Scornik JC., Detection of alloantibodies by flow cytometry: Relevance to clinical transplantation. Cytometry 1995; 22: 259-263.
25. Coupel S, Giral-Classe M, Karam G, et al. Ten-year survival of second kidney transplants: Impact of immunologic factors and renal function at 12 months. Kidney Int 2003; 64: 674-680.